Sanbornton, NH, United States of America

Graham Johnson

This inventor holds 53 USPTO granted patents and 10 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D). Top assignees: Columbia University, Bristol-Myers Squibb Compnay, University of Washington. Active years: 1996-2026.

USPTO Granted Patents = 53 (Patent Applications = 10)

% Patents Active = 94.3

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 12)

Average Co-Inventor Count = 5.7

ph-index = 13

Forward Citations = 353(Granted Patents)

Forward Citations (Not Self Cited) = 241(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Madison, CT (US) (1996 - 2017)
Sanbornton, NH (US) (2016 - 2024)

Company Filing History:

Bristol-Myers Squibb Compnay

patents

5 out of 2,165

University of Washington

Fred Hutchinson Cancer Center

patents

6. 4 out of 3,067

The General Hospital Corporation

patents

7. 3 out of 4

Eleusis Therapeutics US, Inc.

patents

8. 3 out of 3,688

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

9. 2 out of 24

Melinta Therapeutics, Inc.

patents

10. 2 out of 2

Oricula Therapeutics LLC

patents

11. 2 out of 15,964

University of California

patents

12. 1 out of 97

Albany Molecular Research, Inc.

patents

13. 1 out of 17

Rib-X Pharmaceuticals, Inc.

patents

14. 1 out of 462

Science Applications International Corporation

patents

where one patent can have more than one assignee

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

Psilocin Salts

4-Phenylpiperidines

Gamma-Secretase Modulators

Indole Compounds

mRNA Splicing

Chiral Indole Compounds

Benzoxazole Derivatives

Arylalkylbenzofuran Derivatives

Octahydropyrrolopyrroles

Sensory Hair Cell Death

Quinolone Compounds

N-Alkyl-2-Phenoxyethanamines

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12545642 - Pharmaceutically acceptable salts of psilocin and uses thereof (2026-02-10),

2. 12473302 - 4-phenylpiperidines, their preparation and use (2025-11-18),

3. 12404277 - Substituted 4-phenylpiperidines, their preparation and use (2025-09-02),

4. 11919913 - 4-phenylpiperidines, their preparation and use (2024-03-05),

5. 11891386 - Indole compounds and their use (2024-02-06),

6. 11779573 - Crystalline forms of compounds for preventing or treating sensory hair cell death (2023-10-10),

7. 11702417 - Compounds for improving mRNA splicing (2023-07-18),

8. 11680043 - Pharmaceutically acceptable salts of psilocin and uses thereof (2023-06-20),

9. 11649240 - Substituted 4-phenylpiperidines, their preparation and use (2023-05-16),

10. 11459322 - Indole compounds and their use (2022-10-04),

11. 11427576 - Indole compounds and their use (2022-08-30),

12. 11390621 - Chiral indole compounds and their use (2022-07-19),

13. 11312684 - Pharmaceutically acceptable salts of psilocin and uses thereof (2022-04-26),

14. 11117884 - Potent gamma-secretase modulators (2021-09-14),

15. 11028098 - 4-phenylpiperidines, their preparation and use (2021-06-08),

Title: Graham Johnson: Innovator in Pharmaceutical Compounds

Introduction

Graham Johnson, based in Sanbornton, NH, is an accomplished inventor with a remarkable portfolio that includes 50 patents. His innovative work in the pharmaceutical industry has contributed significantly to the development of new compounds and therapies.

Latest Patents

Among his recent patents are innovative compounds such as 4-phenylpiperidines, which focus on their preparation and utility. Additionally, he has developed relevant indole compounds along with pharmaceutical compositions that stimulate the immune system in patients, particularly in the context of cancer treatment. These advancements demonstrate his commitment to enhancing medical science through innovative solutions.

Career Highlights

Graham has had an impactful career at renowned institutions, including Bristol-Myers Squibb Company and Columbia University in the City of New York. His roles in these organizations allowed him to advance his research and push the boundaries of pharmaceutical innovation.

Collaborations

Throughout his career, Graham has collaborated with notable colleagues, including Konstantin Petrukhin and Christopher Cioffi. Their teamwork has fostered a collaborative environment that drives forward-thinking research and development in the pharmaceutical domain.

Conclusion

Graham Johnson exemplifies the spirit of innovation in the pharmaceutical industry. His extensive patent portfolio and collaborative efforts highlight not only his contributions but also his dedication to improving health outcomes through science and technology.